A5047815551- Nanoparticle-Based Drug Delivery
- Cancer Immunotherapy and Biomarkers
- Curcumin's Biomedical Applications
- Extracellular vesicles in disease
- Immunotherapy and Immune Responses
- Nanoplatforms for cancer theranostics
- Dendrimers and Hyperbranched Polymers
Peking University
2024-2025
Beijing University of Chinese Medicine
2023-2024
State Key Laboratory of Natural and Biomimetic Drugs
2024
Cancer patients by immune checkpoint therapy have achieved long-term remission, with no recurrence of clinical symptoms cancer for many years. Nevertheless, more than half are not responsive to this due exhaustion. Here, we report a novel gene engineered exosome which is rationally designed engineering PD1 and simultaneously enveloping an adjuvant imiquimod (PD1-Imi Exo) boosting response blockage therapy. The results showed that PD1-Imi Exo had vesicular round shape (approximately 139 nm),...
Immune checkpoint blockade therapy using programmed cell death 1 (PD1) or ligand (PD-L1) has made significant progress in the treatment of advanced cancers, with some patients achieving long-term remission without clinical recurrence. However, only a minority colon cancer respond to therapy. Here, we report protease-cleavable anti-PD-L1 antibody liposome, eLipo anti-PD-L1, for enhancing In vivo, is cleaved by legumain at site into pegylated and cancer-homing doxorubicin liposome. Functional...
As a first-line anticancer drug, paclitaxel has shortcomings, such as poor solubility and lack of tumour cell selectivity, which limit its further applications in clinical practice. Therefore, the authors aimed to utilise characteristics prodrug nanotechnology prepare reactive oxygen species (ROS) GSH dual-responsive targeted nanoparticle Man-PEG-SS-PLGA/ProPTX improve application status limitation. The characterisation was carried out through preparation. cytotoxicity nanoparticles on cells...